Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial
SAN DIEGO — Ozempic and Wegovy became weight loss sensations by targeting a single hormone, leading people to lose as much as 15% of their weight. But that wasn’t enough — soon there was Mounjaro, which targets two hormones, leading to 21% weight loss.
Now, Eli Lilly has new results showing that an experimental drug that targets three hormones led to 24.2% weight loss in a mid-stage trial, the greatest amount seen yet with an obesity drug.
